Absence of misincorporation of pyrimidines in DNA after treatment with a combination of cisplatin (cis-diammine-dichloro-platinum) and 5-fluorouracil of mouse sarcoma cells

Acta Oncologica

Volumn 35, Issue 2, 1996, Pages 229-235

  Nylén, Urban ^a   Skog, Sven ^a   Lewin, Freddi ^b  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b STOCKHOLM SÖDER HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; DEOXYCYTIDINE TRIPHOSPHATE; FLUOROURACIL; PYRIMIDINE; THYMIDINE TRIPHOSPHATE;

ANIMAL CELL; ARTICLE; ASCITES TUMOR; CONTROLLED STUDY; DNA SYNTHESIS INHIBITION; DRUG POTENTIATION; INTRAPERITONEAL DRUG ADMINISTRATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; SARCOMA CELL;

EID: 0029885723     PISSN: 0284186X     EISSN: None     Source Type: Journal    
DOI: 10.3109/02841869609098506     Document Type: Article

References (27)

1. Dimery IW, Hong WK. Overview of combined modality therapies for head and neck cancer. J Natl Cancer Inst 1993; 85: 95-111.
2. Schabel FM, Trader MW, Laster WR Jr, Corbett TH, Griswold DP Jr. Cis-diamminedichloroplatinum(II): combination chemotherapy and cross-resistance studies with tumors of mice. Cancer Treatm Rep 1979; 63: 1459-73.
3. Scanlon KJ, Newman EM, Lu Y, Priest DG. Biochemical basis for cisplatin and 5-fluorouracil synergism in human ovarian carcinoma cells. Proc Natl Acad Sci USA 1986; 83: 8923-5.
4. Kuroki M, Nakano S, Mitsugi K, et al. In vivo comparative therapeutic study of optimal administration of 5-fluorouracil and cisplatin using a newly established HST-1 human squamouscarcinoma cell line. Cancer Chemother Pharmacol 1992; 29: 273-6.
5. Lewin F, Skog S, Tribukait B, Ringborg U. Effect of combined treatment with cisplatin and 5-fluorouracil on cell growth and cell cycle kinetics of a mouse ascites tumor growing in vivo. In Vivo 1990; 4: 277-82.
6. Shirasaka T, Shimamoto Y, Ohshimo H, Kimura A, Fukoshima M. Mechanism for synergistic antitumor effect in the combination of 5-fluorouracil with cisplatin in vivo tumor models: from the view of biochemical modulation of 5-fluorouracil. Jpn J Cancer Chemother 1991; 18: 403-9.
7. Esaki T, Nakano S, Tatsumoto T, et al. Inhibition by 5-fluorouracil of cis-diamminedichloroplatinum(II)-induced DNA interstrand cross-link removal in a HST-human squamous carcinoma cell line. Cancer Res 1992; 52: 6501-6.
8. Lewin F, Skog S, Tribukait B, Ringborg U. Cell death in relation to cell cycle in a mouse ascites tumor growing in vivo after combined treatment with cisplatin and 5-flurouracil. Anti Cancer Drugs 1990; 1: 37-44.
9. Lewin F, Ringborg U, Skog S, Tribukait B. The effect of 5-fluorouracil on cisplatin induced DNA interstrand cross-linking in a mouse ascites tumor growing in vivo. Anticancer Drugs 1995; 6: 465-70.
10. Skog S, Lewin F, Heiden T, Tribukait B. DNA synthesis after combined treatment with cisplatin and 5-fluorouracil of a mouse ascites tumor growing in vivo. Anti Cancer Drugs 1994; 5: 83-9.
11. Kunz BA. Mutagenesis and deoxyribonucleotide pool imbalance. Mutat Res 1988; 200: 133-47.
12. Meuth M. The molecular basis of mutations induced by deoxyribonuleoside triphosphate pool imbalances in mammalian cells. Exp Cell Res 1989; 181: 305-16.
13. Phear G, Nalbantoglu J, Meuth M. Next-nucleotide effects in mutations driven by DNA precursor pool imbalances at the aprt locus of Chinese hamster ovary cells. Proc Natl Acad Sci USA 1987; 84: 4450-4.
14. Castro J. Preparation of cell nuclei from fresh tissues for high-quality DNA flow cytometry. Cytometry 1993; 14: 793-804.
15. Garrett C, Santi D. A rapid and sensitive high pressure liquid chromatography assay for deoxyribonucleoside triphosphates in cell extracts. Anal Biochem 1979; 99: 268-73.
16. Cariello NF, Keohavong P, Kat AG, Thilly WG. Molecular analysis of complex human cell populations: mutational spectra of MNNG and ICR-191. Mutat Res 1990; 231: 165-76.
17. Cariello NF, Swenberg JA, Skopek TR. In vitro mutational specificity of cisplatin in the human hypoxanthine guanine phosphoribosyltransferase gene. Cancer Res 1992; 52: 2866-73.
18. Osanto S, Thijssen JCP, Woldering VM, van Rijn JLS, Nataragan A, Tates AD. Increased frequency of chromosomal damage in peripheral blood lymphocytes up to nine years following curative chemotherapy of patients with testicular carcinoma. Environ Mol Mutagen 1991; 17: 71-8.
19. Spyrou G, Reichard P. Compartmentation of dCTP pools. J Biol Chem 1987; 262: 16425-32.
20. Oswald CB, Chancy SG, Hall I. Inhibition of nucleic acid synthesis in P388 lymphocytic leukemia cells in culture by cis-platinum derivatives. Biomed Biochim Acta 1990; 49: 579-87.
21. Sorenson CM. Influence of cis-diamminedichloroplatinum(II) on DNA synthesis and cell cycle progression in excision repair proficient and deficient chinese hamster ovary cells. Cancer Res 1988; 48: 6703-7.
22. Lewin F, Skog S, Tribukait B, Ringborg U. Effect of 5-fluorouracil on the cell growth and cell cycle kinetics of a mouse ascites tumor growing in vivo. Acta Oncol 1987; 26: 125-31.
23. Pinedo HM. Fluorouracil: biochemistry and pharmacology. J Clin Oncol 1988; 6: 1653-64.
24. Rubin E, Kharbanda S, Gunji H, Weichselbaum R, Kufe D. Cis-diamminedichloroplatinum(II) induces c-jun expression in human myeloid leukemia cells: potential involvement of a protein kinase C-dependent signaling pathway. Cancer Res 1992; 52: 878-82.
25. Mosseri M, Fingert HJ, Varticovski I, Chokshi S, Isner JM. In vitro evidence that myocardial ischemia resulting from 5-fluorouracil chemotherapy is due to protein kinase C-mediated vasoconstriction of vascular smooth muscle. Cancer Res 1993; 53: 3028-33.
26. Herrick D, Kufe DW. Lethality associated with incorporation of 5-fluorouracil into preribosomal RNA. Mol Pharmacol 1984; 26: 135-40.
27. Ghoshal K. Specific inhibition of pre-ribosomal RNA processing in extracts from the lymphosarcoma cells treated with 5-fluorouracil. Cancer Res 1994; 54: 632-6.